Kabra Drugs Peer Comparison

Snapshot Summary

Kabra Drugs Ltd. significantly lags behind its peers in all key financial metrics, displaying zero growth, profitability, and efficiency. In contrast, companies like Sun Pharma and Cipla show robust growth and profitability, highlighting the challenges faced by Kabra Drugs in a competitive market.

• Kabra Drugs Ltd. shows no revenue growth or profitability metrics, with a PE ratio of -39.84 indicating losses.
• Sun Pharmaceutical Industries and Cipla Ltd. emerge as strong performers with excellent revenue growth and profitability ratios.
• Kabra Drugs has a debt-to-equity ratio of 0, indicating no debt but also raising concerns about potential growth opportunities.

• Sun Pharmaceutical Industries Ltd.: Strong revenue growth at 8.42% YoY and solid profitability metrics with a ROE of 16.13%.
• Cipla Ltd.: Consistent revenue growth of 13.28% YoY, a solid PE of 23.73, and a high ROE of 16.63%.

Stocks	CMP	Market Cap	P/E	ROCE (%)	Debt/Equity
Kabra Drugs Ltd.	₹18.25	₹43.27Cr	-39.84	-	-
SUNPHARMA	₹1,563.35	₹3,75,099.26Cr	87.59	17.60%	0.04
DIVISLAB	₹6,091.05	₹1,61,698.50Cr	73.20	16.46%	-
CIPLA	₹1,587.60	₹1,28,217.27Cr	23.73	22.77%	0.01
TORNTPHARM	₹3,581.55	₹1,21,215.77Cr	61.53	24.28%	0.57
DRREDDY	₹1,280.30	₹1,06,835.27Cr	15.50	26.86%	0.07
MANKIND	₹2,518.95	₹1,03,926.59Cr	55.18	28.38%	0.02

Explore

Watchlists

Command Palette

Kabra Drugs Peer Comparison

Snapshot Summary